Advances and challenges in novel drug delivery systems for glioma therapy
Glioma therapy faces substantial challenges primarily due to the restrictive nature of the blood-brain barrier (BBB), limiting effective drug penetration and reducing therapeutic efficacy. Recent advancements in novel drug delivery systems (DDS), including exosome-mediated carriers, drug conjugates,...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-08-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1655241/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849231595214471168 |
|---|---|
| author | Peipei Ma Yongkang Li Yongkang Li Yingrui Gu Hui Zeng Hongwei Xiang Hongwei Xiang Zhenzhen Cao Zhenzhen Cao Yankun Han Yankun Han Yong Cui Haixiao Liu Haixiao Liu |
| author_facet | Peipei Ma Yongkang Li Yongkang Li Yingrui Gu Hui Zeng Hongwei Xiang Hongwei Xiang Zhenzhen Cao Zhenzhen Cao Yankun Han Yankun Han Yong Cui Haixiao Liu Haixiao Liu |
| author_sort | Peipei Ma |
| collection | DOAJ |
| description | Glioma therapy faces substantial challenges primarily due to the restrictive nature of the blood-brain barrier (BBB), limiting effective drug penetration and reducing therapeutic efficacy. Recent advancements in novel drug delivery systems (DDS), including exosome-mediated carriers, drug conjugates, and ultrasound-assisted delivery, have demonstrated promising results in overcoming these limitations. Exosomes offer superior biocompatibility, efficient BBB crossing, and natural cellular targeting capabilities; drug conjugates enable highly selective drug delivery through tumor-specific ligands; and ultrasound-assisted systems transiently disrupt the BBB to permit greater drug entry. Despite encouraging preclinical and early clinical outcomes, significant translational barriers remain. Challenges such as exosome manufacturing scalability, conjugate stability, and immunogenicity, as well as the optimization of ultrasound protocols, must be thoroughly addressed to achieve clinical translation. Overcoming these hurdles requires ongoing multidisciplinary collaboration and rigorous clinical evaluation. Continued progress in refining these innovative DDS approaches holds the potential to markedly improve therapeutic outcomes and patient prognosis in glioma treatment. |
| format | Article |
| id | doaj-art-c9bbf3065f004ac194a7c1f0b28a5f2a |
| institution | Kabale University |
| issn | 1663-9812 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj-art-c9bbf3065f004ac194a7c1f0b28a5f2a2025-08-21T05:27:13ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122025-08-011610.3389/fphar.2025.16552411655241Advances and challenges in novel drug delivery systems for glioma therapyPeipei Ma0Yongkang Li1Yongkang Li2Yingrui Gu3Hui Zeng4Hongwei Xiang5Hongwei Xiang6Zhenzhen Cao7Zhenzhen Cao8Yankun Han9Yankun Han10Yong Cui11Haixiao Liu12Haixiao Liu13Department of Neurosurgery, Tangdu Hospital, The Fourth Military Medical University, Xi’an, Shaanxi, ChinaDepartment of Neurosurgery, Tangdu Hospital, The Fourth Military Medical University, Xi’an, Shaanxi, ChinaBasic Medical College of The Fourth Military Medical University, Xi’an, Shaanxi, ChinaDepartment of Neurosurgery, Seventh People’s Hospital of Shanghai University of Traditional Chinese Medicine, Shanghai, ChinaDepartment of Neurosurgery, Shanghai Fourth People’s Hospital, Tongji University, Shanghai, ChinaDepartment of Neurosurgery, Tangdu Hospital, The Fourth Military Medical University, Xi’an, Shaanxi, ChinaBasic Medical College of The Fourth Military Medical University, Xi’an, Shaanxi, ChinaDepartment of Neurosurgery, Tangdu Hospital, The Fourth Military Medical University, Xi’an, Shaanxi, ChinaBasic Medical College of The Fourth Military Medical University, Xi’an, Shaanxi, ChinaDepartment of Neurosurgery, Tangdu Hospital, The Fourth Military Medical University, Xi’an, Shaanxi, ChinaBasic Medical College of The Fourth Military Medical University, Xi’an, Shaanxi, ChinaDepartment of Neurosurgery, Seventh People’s Hospital of Shanghai University of Traditional Chinese Medicine, Shanghai, ChinaDepartment of Neurosurgery, Tangdu Hospital, The Fourth Military Medical University, Xi’an, Shaanxi, ChinaDepartment of Biomedical Engineering, Fourth Military Medical University, Xi’an, Shaanxi, ChinaGlioma therapy faces substantial challenges primarily due to the restrictive nature of the blood-brain barrier (BBB), limiting effective drug penetration and reducing therapeutic efficacy. Recent advancements in novel drug delivery systems (DDS), including exosome-mediated carriers, drug conjugates, and ultrasound-assisted delivery, have demonstrated promising results in overcoming these limitations. Exosomes offer superior biocompatibility, efficient BBB crossing, and natural cellular targeting capabilities; drug conjugates enable highly selective drug delivery through tumor-specific ligands; and ultrasound-assisted systems transiently disrupt the BBB to permit greater drug entry. Despite encouraging preclinical and early clinical outcomes, significant translational barriers remain. Challenges such as exosome manufacturing scalability, conjugate stability, and immunogenicity, as well as the optimization of ultrasound protocols, must be thoroughly addressed to achieve clinical translation. Overcoming these hurdles requires ongoing multidisciplinary collaboration and rigorous clinical evaluation. Continued progress in refining these innovative DDS approaches holds the potential to markedly improve therapeutic outcomes and patient prognosis in glioma treatment.https://www.frontiersin.org/articles/10.3389/fphar.2025.1655241/fullgliomadrug delivery systemsblood-brain barrierdrug conjugatesfocused ultrasound |
| spellingShingle | Peipei Ma Yongkang Li Yongkang Li Yingrui Gu Hui Zeng Hongwei Xiang Hongwei Xiang Zhenzhen Cao Zhenzhen Cao Yankun Han Yankun Han Yong Cui Haixiao Liu Haixiao Liu Advances and challenges in novel drug delivery systems for glioma therapy Frontiers in Pharmacology glioma drug delivery systems blood-brain barrier drug conjugates focused ultrasound |
| title | Advances and challenges in novel drug delivery systems for glioma therapy |
| title_full | Advances and challenges in novel drug delivery systems for glioma therapy |
| title_fullStr | Advances and challenges in novel drug delivery systems for glioma therapy |
| title_full_unstemmed | Advances and challenges in novel drug delivery systems for glioma therapy |
| title_short | Advances and challenges in novel drug delivery systems for glioma therapy |
| title_sort | advances and challenges in novel drug delivery systems for glioma therapy |
| topic | glioma drug delivery systems blood-brain barrier drug conjugates focused ultrasound |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2025.1655241/full |
| work_keys_str_mv | AT peipeima advancesandchallengesinnoveldrugdeliverysystemsforgliomatherapy AT yongkangli advancesandchallengesinnoveldrugdeliverysystemsforgliomatherapy AT yongkangli advancesandchallengesinnoveldrugdeliverysystemsforgliomatherapy AT yingruigu advancesandchallengesinnoveldrugdeliverysystemsforgliomatherapy AT huizeng advancesandchallengesinnoveldrugdeliverysystemsforgliomatherapy AT hongweixiang advancesandchallengesinnoveldrugdeliverysystemsforgliomatherapy AT hongweixiang advancesandchallengesinnoveldrugdeliverysystemsforgliomatherapy AT zhenzhencao advancesandchallengesinnoveldrugdeliverysystemsforgliomatherapy AT zhenzhencao advancesandchallengesinnoveldrugdeliverysystemsforgliomatherapy AT yankunhan advancesandchallengesinnoveldrugdeliverysystemsforgliomatherapy AT yankunhan advancesandchallengesinnoveldrugdeliverysystemsforgliomatherapy AT yongcui advancesandchallengesinnoveldrugdeliverysystemsforgliomatherapy AT haixiaoliu advancesandchallengesinnoveldrugdeliverysystemsforgliomatherapy AT haixiaoliu advancesandchallengesinnoveldrugdeliverysystemsforgliomatherapy |